Dose: 2 to 2.5 ng/kg.min
Single Dose: 2.2 (2.25)
Frequency: As recommended.
Route: IV Inf
Instructions: As Required

. It is of Natural origin and belongs to Arachidonic Acid. It belongs to PGI-II agonsit pharmacological group on the basis of mechanism of action and also classified in Sex Hormones and Prostaglandin pharmacological group.The Molecular Weight of Epoprostenol (Na) is 374.50.

Epoprostenol (Na) is contraindicated in conditions like Hemorrhagic diathesis.

Epoprostenol (Na) produces potentially life-threatening effects which include Bradycardia, Vaso-vagal attacks, Low cardiac output, Severe hypertension. which are responsible for the discontinuation of Epoprostenol (Na) therapy.The signs and symptoms that are produced after the acute overdosage of Epoprostenol (Na) include Hypotension, Nausea, Vomiting, Headache, Abdominal cramps, Severe flushing.The symptomatic adverse reactions produced by Epoprostenol (Na) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Vomiting, Flushing, Abdominal colic.

'Epoprostenol (Na) is primarily indicated in conditions like Adult respiratory distress syndrome (ards), Coronary artery disease, Heart failure, Peripheral vascular disease, Primary pulmonary hypertension, Raynaud''s phenomenon.'

No data regarding the interactions of Epoprostenol (Na) was found.

Increased Alkaline Phosphatase Liver Function Test (LFT) Increased level of alanine aminotransferaseIncreased level of Blood urea nitrogen (BUN) concentrationsIncreased in serum creatinin

Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj (reconstituted soln) Store in refrigerator. Do not Freeze. Use within 48 hrs if refrigerated. Vial Store Below 25°C. Do not Freeze. Protect from Sunlight and Moisture.

Abrupt discontinuation of epoprostenol therapy, including sudden reductions in dosage and interuptions in drug delivery may result in symptoms of rebound pulmonary hypertension. Epoprostenol can cause hypotension, it should be used cautiously with other hypotensive drugs to avoid additive effects. Epoprostenol should not be used chronically in patients who develop pulmonary edema (may be associated with veno-occlusive disease) during dose ranging.